All In Biotech

Drug Trial Radar · NCT00724048

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)

Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

227

Actual

Start

Oct 24, 2008

Primary completion

Jul 26, 2010

Study completion Jul 26, 2010

Sponsor

Sponsor type
Industry
First posted
Jul 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.

Conditions

  • Huntington Disease

Interventions

  • ACR16Drug

    ACR16 will be administered per dose and schedule specified in the arm description.

  • PlaceboOther

    Placebo matching to ACR16 will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12Time frame: Baseline, Week 12

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California

    San Diego, California

  • Colorado Neurological Institute

    Littleton, Colorado

  • University of South Florida

    Tampa, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Charlestown, Massachusetts

  • Struthers Parkinson's Center

    Saint Louis Park, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Albany Medical College

    Albany, New York

  • North Shore-LIJ Health System

    Manhasset, New York

  • University of Rochester

    Rochester, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Ohio State University Parkinson's Center

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Tennessee Health Science Center

    Memphis, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Booth Gardner Parkinson's Care Center

    Kirkland, Washington

  • University of Alberta Glenrose Rehab Hospital

    Edmonton, Alberta, Canada

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • The Centre for Addiction and Mental Health

    Markham, Ontario, Canada

  • Parkinsons and Neurodegenerative Disorders Clinic

    Ottawa, Ontario, Canada

  • Hotel-Dieu Hospital-CHUM

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.